Introduction
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL), a member of the TNF family of ligands, is an attractive anticancer agent due to its ability to selectively induce apoptosis in tumor cells but not normal cells (1) (2) (3) . Cytotoxicity of TRAIL is mediated by DR4 and DR5 receptors and the formation of the downstream death inducing signaling complex, which activates apical caspases-8/10 and leads to apoptosis (4, 5) .
Chemotherapeutic application of TRAIL is hindered by acquired resistance to TRAILinduced cell death (6) (7) (8) , conferred by several molecular mechanisms, such as lower expression of DR4 and DR5 and/or higher expression of anti-apoptotic molecules such as antiapoptotic Bcl2 family members (Mcl-1, Bcl-2, and Bcl-xL), c-FLIP, or IAPs, or the homeoprotein Six1 (8) (9) (10) (11) (12) . Identification of sensitizing agents capable of overcoming resistance may therefore facilitate TRAIL-mediated therapy (13) (14) (15) .
Hepatocellular carcinoma (HCC) is the sixth most common solid tumor and the third leading cause of cancer death worldwide. Classical chemotherapy is not currently effective for HCC treatment, while targeted therapy is limited to sorafenib (16, 17) . Current therapeutic strategies for HCC, such as surgical resection, percutaneous ethanol injection, arterial embolization, interventional chemotherapy, and radiofrequency ablation, are complicated by recurrence and metastasis following intervention (18) . Overall recurrence of HCC can exceed 70% (16, 19) , with a 5-year survival rate of stage-2 disease of about 50% (18) , underscoring the need for novel therapeutic strategies including chemoembolization and neoadjuvant therapy before and after surgery, respectively (18) . Some cancer cells, including HCC cells, are resistant to TRAIL (20) . Identification of sensitizing agents capable of improving TRAIL sensitivity may permit TRAIL-mediated therapy. saponin with high pharmacological activity. Rg 3 has anti-hypertensive and cardio-protective effects (21) and modulates the function of the central and peripheral nervous systems, as well as the immune system (22, 23) . Rg 3 may increase the efficacies of cancer chemotherapy, possibly through inhibitory effects on NF-κB and AP-1 (24) .
In this study, we found that Rg 3 renders HCC cells more susceptible to TRAILinduced apoptosis through upregulation of DR5. This upregulation is mediated through upregulation of CHOP (C/EBP homology protein), which acts on the DR5 promoter. This regulation occurs in cancer cells but not in normal cells, allowing for cancer-specific toxicity.
Rg 3 , in combination with TRAIL, inhibits tumor growth in mouse xenografts, suggesting that Rg 3 may be a sensitizing agent capable of improving sensitivity or overcoming TRAIL resistance and may facilitate the establishment of TRAIL-mediated combination treatment of hepatocellular carcinoma.
Materials and Methods

Reagents.
Recombinant human TRAIL and anti-DR5 antibody were from Koma biotechnologies. AntiCaspase 3, anti-PARP, anti-phospho-eIF2α, and anti-CHOP antibodies were from Cell signaling. Anti-DR4 antibody was from Rockland. Anti-tubulin antibody was from Abcam and anti-GRP78 antibody was from Stressgen. zVAD was from R&D systems. Anti-actin antibody, thapsigargin, necrostatin-1, N-acetylcysteine (NAC), and BHA were from Sigma.
Cycloheximide and actinomycin D were from Calbiochem. Glutathione S-transferase (GST)-TRAIL was described previously (13) . 1.6 kg of Sun Ginseng (heat treated ginseng) was extracted with 70% MeOH (1.2 L) under reflux for 3 h. The solvent was removed in vacuo to yield 320 g of 70% MeOH extract, which was suspended in water and extracted with n-BuOH. The n-BuOH fraction was concentrated in vacuo to yield 91.5 g of BuOH fraction. 40 g of the fractions were subjected to silica gel column chromatography. Nine fractions were obtained using stepwise gradient elution 
Cell culture.
SK-Hep1, HepG2, Hep3B, HT-29, and HeLa cells were cultured in DMEM with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin.
Huh-7 cells were cultured in RPMI 1640 with 10% FBS, 2 mM glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin. The normal liver cell line HL-7702 was purchased from Shanghai Institute of Cell Biology (Shanghai, China) and cultured in RPMI 1640 with 20% FBS, 2 mM glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin. No further authentication of cell lines was done by the authors.
Western blot analysis.
Cells were lysed in M2 buffer (20 mM Tris at pH 7, 0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM DTT, 0.5 mM PMSF, 20 mM β-glycerol phosphate, 1 mM 
Cytotoxicity assay.
Cell viability was determined using tetrazolium colorimetric tests (MTT test), with absorbance read at 570 nm. Representative images were taken by phase-contrast microscopy.
Presented data were from representative experiments of at least 3 independent assays. 
Reverse Transcription-PCR.
RNA was extracted using RNeasy (Qiagen). 1 μg of total RNA from each sample was used for cDNA synthesis with reverse transcriptase (Invitrogen). Equal amounts of cDNA product were used in PCR performed using the Taq DNA polymerase (Takara). PCR amplification was performed using the following primers: DR5 sense (5ƍ-AAGACCCTTGTGCTCGTTGTC-3ƍ), DR5 antisense (5ƍ-GACACATTCGATGTCACTCCA-3ƍ), β-actin sense (5ƍ-CAGGTCATCACCATTGGCAATGAGC-3ƍ), β-actin antisense (5ƍ-GATGTCCACGTCACACTTCATGA-3ƍ).
The final PCR products were resolved in 1.5% agarose gel and stained with ethidium bromide. 
Statistical analysis.
Statistical analysis was performed using ANOVA and an unpaired two-tailed Studentƍs t-test.
Statistical calculations were performed using SPSS software for Windows Version 10.0 (SPSS, Chicago, IL). Earlier studies suggested that Rg 3 might have anti-tumor functions, including inhibition of tumor cell proliferation, invasion, and metastasis, as well as induction of differentiation and apoptosis (26, 27) . In HepG2 cells, Rg 3 alone at concentrations up to 100 μM did not induce morphological signs of cell death (Supplemental Figure 1A) , and cell viability was not Figure 5D , left subpanel). This potentially explains why it is unable to sensitize normal cells to TRAIL ( Figure 1D and Figure 5D , right subpanel). HL7702 cells were capable of dying a caspase-dependent death in response to TRAIL when sensitized by cycloheximide (Supplemental Figure 5A and 
Results
Rg
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Discussion
TRAIL is selectively cytotoxic in cancer cells and is therefore a promising anticancer therapeutic agent (34, 35) . However, acquisition of TRAIL resistance presents a major obstacle in therapy. One strategy to overcome this obstacle is to combine TRAIL with other anti-cancer agents (15) . Here we investigated the ability of Rg 3 to modulate TRAIL signaling in cancer cells. We found Rg 3 is capable of sensitizing TRAIL-induced apoptosis in hepatocellular carcinoma cells by inducing DR5 expression, which is mediated through CHOP upregulation.
Although most cancer cells express DR4 and DR5, the expression level of receptors plays a critical role in determining cell fate in response to TRAIL (36) . Numerous studies 
have shown convincing data that the upregulation of DR4 and DR5 can sensitize to TRAILinduced apoptosis (37, 38) . Several studies have shown that chemotherapy often sensitizes cancer cells to TRAIL by heightening the activation of the mitochondria-dependent caspase activation cascade (39, 40) . In our study, Rg 3 -induced sensitization on TRAIL-induced cell death is mainly executed via modulation of DR5. Numerous mechanisms have been described for induction of the DR5, including ER stress, ROS generation, p53 induction, and NF-κB, and MAPK activation (38, (41) (42) (43) . ROS did not appear to have a role in mediating the effects of Rg 3 on TRAIL-induced apoptosis in our hands. While we saw that Rg 3 activated MAP kinases, the inhibition of kinase activity by a pharmacological inhibitor of JNK, SP600125, or ERK inhibitors, PD98059 and U0126 did not attenuate DR5 upregulation upon without substantially affecting ER stress markers such as p-eIF2α and GRP78. Additionally, Rg 3 is unable to induce CHOP expression and TRAIL sensitization in the normal hepatocyte cell line HL7702 though Tg was able to do so to some extent, suggesting that CHOP upregulation by Rg 3 is not due to the same ER stress pathway as Tg, or that there may be substantial differences in the magnitude of ER stress in response to these two agents. As discussed above, our data here (and also unpublished data) suggest that many of the candidate pathways for upregulation of CHOP by Rg 3 , including ER stress, ROS intermediates, and stress-activated MAP kinase pathways are not involved in DR5 upregulation by CHOP.
Further investigation into how Rg 3 leads to CHOP expression is warranted.
Previous studies have shown that Rg 3 has cytotoxic or cytostatic effects in HCC cells on its own (48) (49) (50) . We observed very little single agent cytotoxic activity of Rg 3 in our in vitro experiments, though there was some anti-tumor activity in vivo. The discrepancies with previous studies may be due to differences in time courses or to purity of the compound or the use of the 20(R) enantiomer of Rg 3 in the previous studies ( Figure 7) . We used the pure 20(S) enantiomer because of its superior solubility compared to the 20(R) enantiomer, making the 20(S) enantiomer a better choice for pharmaceutical development. pharmacokinetic information, the dose of the drug that we used (20 mg/kg) sensitizes HCC cells to TRAIL in vivo without cytotoxicity, indicating that Rg 3 may be likely to achieve a clinically efficacious dose. Thus, our study indicates a novel anti-cancer effect of Rg 3 and supports the further development of Rg 3 as a chemosensitizer in combined therapy with TRAIL to increase the efficacy of its anti-tumor activity. 
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